PET brain imaging revealed that cannabis users with trauma-related psychopathology had 15-20% higher levels of mGlu5 receptors in frontal and limbic brain regions — a receptor at the intersection of the endocannabinoid and glutamate systems.
Read this if you're interested in the neuroscience of why cannabis and trauma are so frequently linked — this PET imaging study reveals a receptor-level connection that goes beyond the endocannabinoid system.
What the researchers found
The endocannabinoid system and the glutamate system are deeply intertwined in the brain, and both are implicated in trauma-related conditions and cannabis use. This study used PET brain imaging to measure a specific receptor — metabotropic glutamate receptor 5 (mGlu5) — that sits at this intersection, in people with trauma-related psychopathology who did and didn't use cannabis.
Among 55 individuals with trauma-related mental health conditions, those who had used cannabis in the past year showed 18.6-19.1% higher mGlu5 availability in frontal brain regions and 14.2-16.6% higher levels in limbic regions (including the amygdala and hippocampus) compared to non-users. Monthly users showed similar elevations.
Why does this matter? mGlu5 receptors regulate glutamate signaling — the brain's primary excitatory system — and are directly modulated by endocannabinoids. Higher mGlu5 levels could reflect a compensatory response to cannabis exposure, an underlying vulnerability that both predisposes to cannabis use and worsens trauma responses, or an adaptive change that affects how the brain processes threatening information.
The orbitofrontal cortex and amygdala — two regions showing elevated mGlu5 — are central to threat processing, emotional regulation, and the fear circuitry disrupted in PTSD. If cannabis use alters glutamate receptor levels in these specific regions, it could change how trauma survivors process threatening stimuli and regulate emotional responses.
This is the first study to directly investigate the cannabis-mGlu5 relationship in people with trauma-related conditions, opening a new molecular window into why cannabis and trauma are so frequently linked.
Why it matters
Most research on cannabis and the brain focuses on the CB1 receptor. This study reveals that cannabis use also affects glutamate receptors — through a different neurotransmitter system — in brain regions critical for trauma processing. This cross-system effect could help explain why cannabis has such complex relationships with mental health: it's not just affecting the endocannabinoid system, it's reshaping glutamate signaling in emotion-regulation circuits.
The numbers in context
55 participants with trauma-related psychopathology. Past-year cannabis users (n=22): 18.62-19.12% higher mGlu5 in frontal ROIs, 14.24-16.55% higher in limbic ROIs. Past-month/monthly users (n=16): 18.05-20.62% higher in frontal, 15.53-16.83% higher in limbic ROIs. Key regions: orbitofrontal cortex and amygdala.
How the study worked
Cross-sectional PET imaging study using [18F]FPEB to measure mGlu5 receptor availability in vivo. 55 individuals with trauma-related psychopathology (cross-diagnostic sample). Compared mGlu5 levels in frontolimbic regions of interest (dorsolateral prefrontal cortex, orbitofrontal cortex, ventromedial prefrontal cortex, amygdala, hippocampus) between cannabis users and non-users. Tested both past-year use (n=22) and past-month/monthly use (n=16).
Who was studied
N=55 adults with trauma-related psychopathology, mixed sex, US-based sample.
What this study cannot tell us
Cross-sectional — can't determine whether cannabis caused the mGlu5 elevation or whether higher baseline mGlu5 predisposes to cannabis use. Small sample (55 total, 22 cannabis users). Cross-diagnostic sample (various trauma-related conditions) rather than a specific diagnosis like PTSD. No healthy control group without trauma exposure. Cannabis use was categorized broadly (past-year/past-month) without dose, potency, or product data. PET imaging measures receptor availability, which reflects a combination of receptor density and binding affinity.
How to read the evidence
Cross-sectional PET imaging study with a modest sample size. The imaging data is rigorous (validated radiotracer, well-defined regions of interest), but the cross-sectional design and small sample limit causal inference.
When this study was published
Published in 2024. mGlu5 as a biomarker for cannabis-trauma interaction is a novel research direction.
The bigger picture
This adds a molecular dimension to the PTSD-cannabis cluster (RTHC-00116, 00117, 00125, 00127). Those studies documented the behavioral relationships — PTSD drives cannabis use, cannabis use affects treatment engagement, psychological inflexibility mediates the link. This study shows what's happening in the brain: mGlu5 receptor changes in the exact circuits that process threat and regulate emotion. It also connects to the neuroscience of the dopamine-endocannabinoid interaction (RTHC-00072, 00073) by revealing that cannabis effects extend beyond the endocannabinoid system into glutamate signaling.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Does cannabis directly cause mGlu5 upregulation, or do people with higher baseline mGlu5 preferentially use cannabis? Would these mGlu5 changes reverse with cannabis cessation? Could mGlu5 be a treatment target for co-occurring cannabis use and PTSD? Do the frontal mGlu5 changes affect decision-making and impulse control in trauma-exposed cannabis users?
Read the original research
Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.
The international journal of neuropsychopharmacology, 27(10)
The International Journal of Neuropsychopharmacology is a reputable journal focused on the intersection of neuroscience and pharmacology.
Citation
Weiss, Emily R; Davis, Margaret T; Asch, Ruth H; D'Souza, Deepak Cyril; Cool, Ryan; Esterlis, Irina. (2024). Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.. The international journal of neuropsychopharmacology, 27(10). https://doi.org/10.1093/ijnp/pyae044
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)
- Why Does Weed Make You Emotional? THC and Emotional Processing
- THC and Studying: What the Research Says About Cannabis and Learning